Individual and combining effects of anti-RANKL monoclonal antibody and teriparatide in ovariectomized mice.

Tokuyama N, Hirose J, Omata Y, Yasui T, Izawa N, Matsumoto T, Masuda H, Ohmiya T, Yasuda H, Saito T, Kadono Y, Tanaka S

Bone reports21 Jan 2015Cited by 19 (Europe PMC)

PMID28377948PMCIDPMC5365172DOI10.1016/j.bonr.2014.12.002PepBankPUB-28377948

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized mice, antibody plus teriparatide increased distal femur BMD compared with antibody alone.
In plain wordsIn mice, antibody plus teriparatide increased distal femur bone density compared with antibody alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseDistal femur BMD
Study
mousen: not reported in source
ovariectomized C57BL/6 mice
Comparator
anti-RANKL antibody alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 μg/kg daily · injection · 4 weeksAs given in this study (mouse).
Source sentences
Summary
Compared with Ab group, Ab + PTH group showed a significant increase in BMD at distal femur and femoral shaft.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined the individual and combined effects of teriparatide and anti-RANKL (receptor activator of nuclear factor κB ligand) monoclonal antibody in ovariectomized mice. Three-month-old female C57BL/6 mice were ovariectomized (OVX) or sham operated.
Report a problemFND-2837794801
02AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized mice, antibody plus teriparatide increased femoral shaft BMD compared with antibody alone.
In plain wordsIn mice, antibody plus teriparatide increased femoral shaft bone density compared with antibody alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral shaft BMD
Study
mousen: not reported in source
ovariectomized C57BL/6 mice
Comparator
anti-RANKL antibody alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 μg/kg daily · injection · 4 weeksAs given in this study (mouse).
Source sentences
Summary
Compared with Ab group, Ab + PTH group showed a significant increase in BMD at distal femur and femoral shaft.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined the individual and combined effects of teriparatide and anti-RANKL (receptor activator of nuclear factor κB ligand) monoclonal antibody in ovariectomized mice. Three-month-old female C57BL/6 mice were ovariectomized (OVX) or sham operated.
Report a problemFND-2837794802
03AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized mice, teriparatide alone increased cortical bone volume compared with antibody alone.
In plain wordsIn mice, teriparatide alone increased cortical bone volume compared with antibody alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical bone volume with teriparatide alone
Study
mousen: not reported in source
ovariectomized C57BL/6 mice
Comparator
anti-RANKL antibody alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 μg/kg daily · injection · 4 weeksAs given in this study (mouse).
Source sentences
Summary
Cortical bone volume was significantly increased in PTH and Ab + PTH groups compared with Ab group.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined the individual and combined effects of teriparatide and anti-RANKL (receptor activator of nuclear factor κB ligand) monoclonal antibody in ovariectomized mice. Three-month-old female C57BL/6 mice were ovariectomized (OVX) or sham operated.
Report a problemFND-2837794803
04AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized mice, antibody plus teriparatide increased cortical bone volume compared with antibody alone.
In plain wordsIn mice, antibody plus teriparatide increased cortical bone volume compared with antibody alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical bone volume with add-on teriparatide
Study
mousen: not reported in source
ovariectomized C57BL/6 mice
Comparator
anti-RANKL antibody alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 μg/kg daily · injection · 4 weeksAs given in this study (mouse).
Source sentences
Summary
Cortical bone volume was significantly increased in PTH and Ab + PTH groups compared with Ab group.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined the individual and combined effects of teriparatide and anti-RANKL (receptor activator of nuclear factor κB ligand) monoclonal antibody in ovariectomized mice. Three-month-old female C57BL/6 mice were ovariectomized (OVX) or sham operated.
Report a problemFND-2837794804
05AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized mice, antibody plus teriparatide suppressed bone turnover to the same degree as antibody alone.
In plain wordsIn mice, antibody plus teriparatide suppressed bone turnover to the same degree as antibody alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBone turnover
Study
mousen: not reported in source
ovariectomized C57BL/6 mice
Comparator
anti-RANKL antibody alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 μg/kg daily · injection · 4 weeksAs given in this study (mouse).
Source sentences
Summary
Bone turnover in Ab + PTH group was suppressed to the same degree as in Ab group.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined the individual and combined effects of teriparatide and anti-RANKL (receptor activator of nuclear factor κB ligand) monoclonal antibody in ovariectomized mice. Three-month-old female C57BL/6 mice were ovariectomized (OVX) or sham operated.
Report a problemFND-2837794805

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

06AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In ovariectomized mice, TRAP-positive multinucleated cell counts fell markedly in both antibody and antibody-plus-teriparatide groups.
In plain wordsIn mice, TRAP-positive cell counts fell in both antibody and antibody-plus-teriparatide groups. The abstract does not name the comparator.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTRAP-positive multinucleated cells
Study
mousen: not reported in source
ovariectomized C57BL/6 mice
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The number of TRAP-positive multinucleated cells was markedly reduced in Ab and Ab + PTH groups.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined the individual and combined effects of teriparatide and anti-RANKL (receptor activator of nuclear factor κB ligand) monoclonal antibody in ovariectomized mice. Three-month-old female C57BL/6 mice were ovariectomized (OVX) or sham operated.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2837794806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.